•Introducing a high-capacity microfluidic platform specifically designed for neuroscience drug discovery
•Enabling the study of neurological processes in vitro, such as uptake and propagation of misfolded proteins, synaptic transmission and cellular interactions, or axonal degeneration and regeneration
Johan Pihl, Chief Scientific Officer, Cellectricon